Ó³»­´«Ã½

Pinto L, Goard MJ, Estandian D, et al. Fast modulation of visual perception by basal forebrain cholinergic neurons. Nat Neurosci. 2013;16(12):1857-1863. doi:10.1038/nn.3552

Loebrich S, Djukic B, Tong ZJ, Cottrell JR, Turrigiano GG, Nedivi E. Regulation of glutamate receptor internalization by the spine cytoskeleton is mediated by its PKA-dependent association with CPG2. Proc Natl Acad Sci U S A. 2013;110(47):E4548-56. doi:10.1073/pnas.1318860110

McCarroll SA, Hyman SE. Progress in the genetics of polygenic brain disorders: significant new challenges for neurobiology. Neuron. 2013;80(3):578-87. doi:10.1016/j.neuron.2013.10.046

Ting JT, Feng G. Development of transgenic animals for optogenetic manipulation of mammalian nervous system function: progress and prospects for behavioral neuroscience. Behav Brain Res. 2013;255:3-18. doi:10.1016/j.bbr.2013.02.037

Ripke S, O’Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013;45(10):1150-9. doi:10.1038/ng.2742

Wagner FF, WeÑ—wer M, Lewis MC, Holson EB. Small molecule inhibitors of zinc-dependent histone deacetylases. Neurotherapeutics. 2013;10(4):589-604. doi:10.1007/s13311-013-0226-1

Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee H, Ripke S, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013;45(9):984-94. doi:10.1038/ng.2711

Weïwer M, Lewis MC, Wagner FF, Holson EB. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia. Future Med Chem. 2013;5(13):1491-508. doi:10.4155/fmc.13.141

Schroeder FA, Chonde DB, Riley MM, et al. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors. Neurosci Lett. 2013;550:119-24. doi:10.1016/j.neulet.2013.06.016

Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12(8):581-94. doi:10.1038/nrd4051